SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 694.75-0.1%2:40 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Miljenko Zuanic3/14/2019 1:32:16 PM
  Read Replies (1) of 3557
 
Finally, CMS drug spending (Par B too) for 2017 are out:
portal.cms.gov

Eylea: $2.466M (229.5K beneficiary) for 2017 v $2.221M (210.4K beneficiary) for 2016, 11% growth
Lucentis: $1.038M (105.2K beneficiary) for 2017 v $1.044 M (106.4K beneficiary) for 2016. ~ FLAT

Interesting that spending per beneficiary for E is $10751 v $9865 for L, while we know that E bring significant more value than L.

SO, ICER should stop FUCKING OUT about drug price debate (political issue), and focus instead and comparative drug market value (that suppose be their focus).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News